Tucked inside Trump's drug-pricing executive order is an apparent threat to withdraw drugmakers' medicines if they do not lower prices

The package revives President Donald Trump’s much-maligned Most Favored Nation rule but goes further into the private markets and beyond, leveraging the patent system, drug importation and more.

The pharmaceutical industry, which is well known for its well-resourced lobbying campaigns, has a lesser-known tactic for influencing policy: bankrolling ostensibly independent nonprofit organizations

By Steve Holland, Michael Erman and Patrick Wingrove WASHINGTON (Reuters) -U.S. President Donald Trump signed a wide-reaching executive order on Monday directing drugmakers to lower the prices of their medicines to align with what other countries pay that analysts and legal experts said would be difficult to implement.

President Trump's executive order on drug pricing caused a surprising rally in pharmaceutical stocks. Read my analysis of PJP ETF.

Antibiotics, antidepressants and other drugs frequently leach into the environment, where they can impact ecosystems and human health.

President Donald Trump on Monday signed an executive order reviving a controversial plan to lower prescription drug costs by linking the price of certain medications in the U.S. to their lower prices in other countries.

Analysts have given Lexicon Pharmaceuticals a total of 5 ratings, with the consensus rating being Buy. The average one-year price target is $3.8, indicating a potential 442.08% upside.

By Chioma Obinna The Director-General of the National Agency for Food and Drug Administration and Control, NAFDAC, Prof Mojisola Adeyeye, has called for a strategic partnership between Nigeria’s pharmaceutical industry and academic institutions to enhance local development of medicines and vaccines,

The conditions in orbit cannot be replicated on our planet, so scientists on the ground develop pharmaceutical predictions and test them by sending modules to space. The drugs are